SCHEMBL6323476

SCHEMBL6323476

c1ccc(Nc2ncc3ncccc3n2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK10 P53779 1/20 0.47
GFER P55789 1/20 0.47
CCNA2 P20248 3/20 0.47
CDK2 P24941 3/20 0.47
CCND3 P30281 3/20 0.47
CCNK O75909 1/20 0.47
CDK9 P50750 1/20 0.47
CDK6 Q00534 1/20 0.47
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
FLT3 P36888 1/20 0.44
TYRO3 Q06418 1/20 0.44
MERTK Q12866 1/20 0.44
GAS6 Q14393 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133352 0.85 KMT2A (0.48) MEN1KMT2AMAPK10GFERCCNA2
SCHEMBL4047005 0.81 CDK2 (0.50) MEN1KMT2ACDK2NPC1RAB9A
SCHEMBL6402766 0.77 KMT2A (0.47) MEN1KMT2AMAPK10GFERCCNA2
SCHEMBL6486739 0.77 MKNK1 (0.45) MEN1KMT2ACCNA2CDK2CCND3
SCHEMBL4551624 0.76 FLT3 (0.44) MEN1KMT2AMAPK10GFERCCNA2
SCHEMBL1883319 0.74 KMT2A (0.57) MEN1KMT2AMAPK10GFERCCNA2
SCHEMBL5496713 0.74 CCND3 (0.46) MEN1KMT2AMAPK10GFERCCNA2
SCHEMBL1701931 0.74 PDGFRB (0.62) MEN1KMT2AMAPK10GFERCDK2
SCHEMBL3951276 0.73 MEN1 (0.67) MEN1KMT2AMAPK10GFERALDH1A1
SCHEMBL29544002 0.73 MEN1 (0.67) MEN1KMT2AMAPK10GFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111297867-A Use of composition containing pyridylaminopyridopyrimidine derivative for preparing medicine for treating breast cancer 黄泳华 2020-06-19 CN claimed
CN-110623959-A Compositions containing mixtures of pyridylaminopyridopyrimidine derivatives and their use 黄泳华 2019-12-31 CN claimed
CN-111297867-A Use of composition containing pyridylaminopyridopyrimidine derivative for preparing medicine for treating breast cancer 黄泳华 2020-06-19 CN disclosed
CN-111297867-A Use of composition containing pyridylaminopyridopyrimidine derivative for preparing medicine for treating breast cancer 黄泳华 2020-06-19 CN disclosed
CN-111297867-A Use of composition containing pyridylaminopyridopyrimidine derivative for preparing medicine for treating breast cancer 黄泳华 2020-06-19 CN disclosed
CN-110623959-A Compositions containing mixtures of pyridylaminopyridopyrimidine derivatives and their use 黄泳华 2019-12-31 CN disclosed
CN-110623959-A Compositions containing mixtures of pyridylaminopyridopyrimidine derivatives and their use 黄泳华 2019-12-31 CN disclosed
CN-110623959-A Compositions containing mixtures of pyridylaminopyridopyrimidine derivatives and their use 黄泳华 2019-12-31 CN disclosed
US-6960662-B2 Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones WARNER-LAMBERT COMPANY (US) 2005-11-01 US disclosed
US-20030216415-A1 Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones BEYLIN VLADIMIR GENUKH (US) 2003-11-20 US disclosed
EP-1307451-A2 PROCESS FOR PREPARING 2-(4-PYRIDYL)AMINO-6-DIALKYLOXYPHENYL-PYRIDO 2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2003-05-07 EP disclosed
WO-2002012237-A2 PROCESS FOR PREPARING 2-(4-PYRIDYL)AMINO-6-DIALKYLOXYPHENYL-PYRIDO[2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY (US) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216415-A1 Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones DPYD, PDXK, PARP2 MEN1 3451/4885KMT2A 1204/4885MAPK10 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.